Compare Procter & Gamble Co (PG) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Revvity Inc — how do they compare? Procter & Gamble Co trades at $151.06 (market cap $349.77B), while Revvity Inc trades at $154.78 (market cap $16.98B). The key difference: Procter & Gamble Co is far larger — about 20.6× Revvity Inc's market cap, and Procter & Gamble Co pays the higher dividend (2.89%). Which is the better fit depends on your goals — on Pluang, investors hold Procter & Gamble Co for 131 Days and Revvity Inc for 12 Days on average.
| PG | RVTY | |
|---|---|---|
Market Cap | $349.77B | $16.98B |
Volume | 10,055,825 | 1,456,900 |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $157.36 |
52-Week Low | $138.10 | $82.26 |
Typical Hold Time | 131 Days | 12 Days |
Enterprise Value | $375.61B | $19.30B |
Dividend Yield | 2.89% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $147.82, down 0.4% on the day, showing resilience amid market volatility. The stock maintains a bullish technical signal with strong moving average support and has consistently beaten earnings estimates in recent quarters. PG demonstrates robust fundamentals with $84.28B revenue, 18.44% net margin, and steady dividend payments, though valuation multiples remain elevated versus peers.
PG offers stable growth with dividend reliability but faces premium valuation concerns. The 8.3% upside to consensus target of $160.13 suggests moderate potential, while competitive pressures and soft demand outlook present headwinds. Institutional ownership trends show mixed positioning, requiring careful monitoring of margin sustainability and consumer spending patterns.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
